Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil | Zendy

R. Wüthrich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil

Author(s) -

R. Wüthrich

Publication year - 1999

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/14.2.394

Subject(s) - medicine , azathioprine , regimen , creatinine , transplantation , urology , mycophenolic acid , gastroenterology , mycophenolate , kidney transplantation , renal function , surgery , disease

Several multinational controlled clinical trials have shown that triple therapy immunosuppressive regimens which include mycophenolate mofetil (MMF), cyclosporin A (CSA) and steroids (S) are superior compared with conventional regimens which include azathioprine (AZA), CSA and S, mainly because MMF reduces the rate of acute rejection episodes in the first 6 months after kidney transplantation. Post-marketing studies are useful to evaluate the general applicability and costs of MMF-based immunosuppressive regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research